However, MET amplification has emerged as a significant mechanism of acquired resistance in various targeted therapies (5%–22%), such as EGFR mutation, KRAS G12C mutation, ALK fusion, ROS1 fusion and RET fusion, and particularly in EGFR-mutant NSCLC (7–17). This evidence concerns the gene EGFR and non-small cell lung carcinoma.